Cymabay Therapeu Stock Fundamentals
| CBAYDelisted Stock | USD 11.83 0.27 2.34% |
Cymabay Therapeu fundamentals help investors to digest information that contributes to Cymabay Therapeu's financial success or failures. It also enables traders to predict the movement of Cymabay Stock. The fundamental analysis module provides a way to measure Cymabay Therapeu's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Cymabay Therapeu stock.
Cymabay |
Cymabay Therapeu Company Current Valuation Analysis
Cymabay Therapeu's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Cymabay Therapeu Current Valuation | 3.45 B |
Most of Cymabay Therapeu's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Cymabay Therapeu is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
CompetitionIn accordance with the recently published financial statements, Cymabay Therapeu has a Current Valuation of 3.45 B. This is 75.99% lower than that of the Pharmaceuticals sector and 25.77% lower than that of the Health Care industry. The current valuation for all United States stocks is 79.26% higher than that of the company.
Cymabay Therapeu Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Cymabay Therapeu's current stock value. Our valuation model uses many indicators to compare Cymabay Therapeu value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Cymabay Therapeu competition to find correlations between indicators driving Cymabay Therapeu's intrinsic value. More Info.Cymabay Therapeu is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Cymabay Therapeu's earnings, one of the primary drivers of an investment's value.Cymabay Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cymabay Therapeu's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Cymabay Therapeu could also be used in its relative valuation, which is a method of valuing Cymabay Therapeu by comparing valuation metrics of similar companies.Cymabay Therapeu is currently under evaluation in current valuation category among its peers.
Cymabay Fundamentals
| Return On Equity | -0.64 | |||
| Return On Asset | -0.22 | |||
| Operating Margin | (745.58) % | |||
| Current Valuation | 3.45 B | |||
| Shares Outstanding | 114.78 M | |||
| Shares Owned By Insiders | 0.51 % | |||
| Shares Owned By Institutions | 99.49 % | |||
| Number Of Shares Shorted | 5.85 M | |||
| Price To Earning | (8.62) X | |||
| Price To Book | 12.76 X | |||
| Price To Sales | 119.98 X | |||
| Revenue | 31.07 M | |||
| Gross Profit | (41.63 M) | |||
| EBITDA | (101 M) | |||
| Net Income | (105.37 M) | |||
| Cash And Equivalents | 153.42 M | |||
| Cash Per Share | 1.81 X | |||
| Total Debt | 114.49 M | |||
| Debt To Equity | 1.45 % | |||
| Current Ratio | 12.20 X | |||
| Book Value Per Share | 2.57 X | |||
| Cash Flow From Operations | (72.53 M) | |||
| Short Ratio | 0.84 X | |||
| Earnings Per Share | (0.99) X | |||
| Target Price | 32.5 | |||
| Number Of Employees | 101 | |||
| Beta | 0.32 | |||
| Market Capitalization | 3.73 B | |||
| Total Asset | 434.69 M | |||
| Retained Earnings | (978.23 M) | |||
| Working Capital | 366.96 M | |||
| Current Asset | 42.79 M | |||
| Current Liabilities | 6.15 M | |||
| Z Score | 16.7 | |||
| Net Asset | 434.69 M |
About Cymabay Therapeu Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cymabay Therapeu's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cymabay Therapeu using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cymabay Therapeu based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California. Cymabay Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 59 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Other Consideration for investing in Cymabay Stock
If you are still planning to invest in Cymabay Therapeu check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Cymabay Therapeu's history and understand the potential risks before investing.
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like |